Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy

Endothelin in Renal Physiology and Disease

Volumn 172, Issue , 2011, Pages 223-234

  Lazich, Ivana ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN; ENDOTHELIN RECEPTOR;

DRUG ANTAGONISM; DRUG RESISTANCE; HUMAN; HYPERTENSION; PHYSIOLOGY; RENOVASCULAR HYPERTENSION; REVIEW;

DRUG RESISTANCE; ENDOTHELINS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; RECEPTORS, ENDOTHELIN;

EID: 84926084351     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000328988     Document Type: Chapter

References (71)

1. Schoenborn C, Heyman K: Health characteristics of adults aged 55 years and over:United States, 2004 -2007. National Health Statistics Reports, No.16. Centers for Disease Control and Prevention. 2009. www.cdc.gov (accessed April 2011).
2. Lindholm LH, Ibsen H, Dahlof B. et al:Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-1010.
3. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone:the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-1975.
4. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.
5. 2010 atlas of chronic kidney disease and end-stage renal disease in the United States. United States Renal Data System. 2010. www. USRDS.org (accessed April 2011).
6. Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
7. Kaplan NM: Resistant hypertension. J Hypertens 2005;23:1441-1444.
8. Sarafidis PA, Bakris GL: Resistant hypertension:an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-1757.
9. Persell SD: Prevalence of Resistant Hypertension in the United States, 2003-2008. Hypertension 2011, E-pub ahead of print.
10. Moser M, Setaro JF: Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med 2006;355:385-392.
11. Calhoun DA, Jones D, Textor S, et al:Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117:e510-e526.
12. Barton M, Meyer MR: Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009;54:11-18.
13. Mishra SI, Jones-Burton C, Fink JC, Brown J, Bakris GL, Weir MR: Does dietary salt increase the risk for progression of kidney disease? Curr Hypertens Rep 2005;7:385-391.
14. Sarafidis PA, Bakris GL: State of hypertension management in the United States:confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich ) 2008;10:130-139.
15. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA: Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005;18:805-812.
16. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
17. Grossman E, Messerli FH: Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich ) 2008;10:556-566.
18. Morris MJ: Cardiovascular and metabolic effects of obesity. Clin Exp Pharmacol Physiol 2008;35:416-419.
19. Sarafidis PA: Obesity, insulin resistance and kidney disease risk: insights into the relationship. Curr Opin Nephrol Hypertens 2008;17:450-456.
20. Sarafidis PA, Bakris GL: Review: insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007;92:379-385.
21. Shemyakin A, Salehzadeh F, Bohm F, et al:Regulation of glucose uptake by endothelin-1 in human skeletal muscle in vivo and in vitro. J Clin Endocrinol Metab 2010;95:2359-2366.
22. Ahlborg G, Shemyakin A, Bohm F, Gonon A, Pernow J: Dual endothelin receptor blockade acutely improves insulin sensitivity in obese patients with insulin resistance and coronary artery disease. Diabetes Care 2007;30:591-596.
23. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I, et al: Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 2009;54:98-105.
24. Yanagisawa M, Kurihara H, Kimura S, et al:A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
25. Luscher TF, Barton M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-2440.
26. Yoshizumi M, Kurihara H, Sugiyama T, et al: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem Biophys Res Commun 1989;161:859-864.
27. Bakris GL, Re RN: Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am J Physiol 1993;264:F937-F942.
28. Bakris GL, Fairbanks R, Traish AM: Arginine vasopressin stimulates human mesangial cell production of endothelin. J Clin Invest 1991;87:1158-1164.
29. Hu RM, Levin ER, Pedram A, Frank HJ:Insulin stimulates production and secretion of endothelin from bovine endothelial cells. Diabetes 1993;42:351-358.
30. Zoja C, Orisio S, Perico N, et al: Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-beta, thrombin, and a thromboxane A2 analogue. Lab Invest 1991;64:16-20.
31. Boulanger C, Luscher TF: Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
32. Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F: Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-1 biosynthesis in rat endothelial cells. Endocrinology 1993;133:2474-2480.
33. Sarafidis PA, Bakris GL: Insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab 2007;92:379-385.
34. Ihara M, Noguchi K, Saeki T, et al: Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50:247-255.
35. Hirata Y, Emori T, Eguchi S, et al: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-1373.
36. Lin H, Smith MJ Jr, Young DB: Roles of prostaglandins and nitric oxide in the effect of endothelin-1 on renal hemodynamics. Hypertension 1996;28:372-378.
37. Kohan DE: The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 2006;15:34-40.
38. Tomobe Y, Miyauchi T, Saito A, et al: Effects of endothelin on the renal artery from spontaneously hypertensive and Wistar Kyoto rats. Eur J Pharmacol 1988;152:373-374.
39. Matsuura T, Miura K, Ebara T, et al: Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol 1997;122:81-86.
40. Plato CF, Pollock DM, Garvin JL: Endothelin inhibits thick ascending limb chloride flux via ET(B) receptor-mediated NO release. Am J Physiol Renal Physiol 2000;279:F326-F333.
41. Ge Y, Bagnall A, Stricklett PK, et al:Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 2006;291:F1274-F1280.
42. Ge Y, Bagnall A, Stricklett PK, Webb D, Kotelevtsev Y, Kohan DE: Combined knockout of collecting duct endothelin A and B receptors causes hypertension and sodium retention. Am J Physiol Renal Physiol 2008;295:F1635-F1640.
43. Nakano D, Pollock DM: Contribution of endothelin A receptors in endothelin 1-dependent natriuresis in female rats. Hypertension 2009;53:324-330.
44. Hocher B, Thone-Reineke C, Rohmeiss P, et al: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-1389.
45. Bruzzi I, Corna D, Zoja C, et al: Time course and localization of endothelin-1 gene expression in a model of renal disease progression. Am J Pathol 1997;151:1241-1247.
46. Kawaguchi H, Sawa H, Yasuda H: Effect of endothelin on angiotensin converting enzyme activity in cultured pulmonary artery endothelial cells. J Hypertens 1991;9:171-174.
47. Kawaguchi H, Sawa H, Yasuda H: Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990;22:839-842.
48. Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010;1802:1203-1213.
49. Lehrke I, Waldherr R, Ritz E, Wagner J:Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol 2001;12:2321-2329.
50. Ohta K, Hirata Y, Shichiri M, et al: Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991;39:307-311.
51. Wesson DE, Nathan T, Rose T, Simoni J, Tran RM: Dietary protein induces endothelinmediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007;71:210-217.
52. Sorokin A, Kohan DE: Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 2003;285:F579-F589.
53. Hill GS: Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens 2008;17:266-270.
54. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-923.
55. Pimenta E, Gaddam KK, Oparil S, et al:Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension:results from a randomized trial. Hypertension 2009;54:475-481.
56. Barton M, Yanagisawa M: Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008;86:485-498.
57. Kohan DE: Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010;19:134-139.
58. Yokokawa K, Tahara H, Kohno M, et al:Hypertension associated with endothelinsecreting malignant hemangioendothelioma. Ann Intern Med 1991;114:213-215.
59. Kirchengast M, Luz M: Endothelin receptor antagonists: clinical realities and future directions. J Cardiovasc Pharmacol 2005;45:182-191.
60. Schneider MP, Boesen EI, Pollock DM:Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 2007;47:731-759.
61. Dhaun N, Goddard J, Kohan DE, Pollock DM, Schiffrin EL, Webb DJ: Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension 2008;52:452-459.
62. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V: The effect of an endothelinreceptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998;338:784-790.
63. Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002;15:583-589.
64. Weber MA, Black H, Bakris G, et al: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatmentresistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1423-1431.
65. Bakris GL, Lindholm LH, Black HR, et al:Divergent results using clinic and ambulatory blood pressures: report of a darusentanresistant hypertension trial. Hypertension 2010;56:824-830.
66. Raichlin E, Prasad A, Mathew V, et al:Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008;52:522-528.
67. Opocensky M, Kramer HJ, Backer A, et al:Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension 2006;48:965-971.
68. Goddard J, Johnston NR, Hand MF, et al:Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
69. Dhaun N, Macintyre IM, Kerr D, et al:Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011;57:772-779.
70. Mann JF, Green D, Jamerson K, et al:Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
71. Verhaar MC, Strachan FE, Newby DE, et al:Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998;97:752-756.